Novel nanoscale vehicles for drug delivery
UCL pioneers the engineering of novel nanoscale drug delivery vehicles, which can be tuned to release a range of cargos.
Postnova Analytics reports on the recent investment by the Department of Chemistry at University College London (UCL) in an AF2000 Field Flow Fractionation System to assist them in their development of novel nanoscale vehicles for drug delivery.
UCL has pioneered the engineering of novel nanoscale drug delivery vehicles which can be tuned to release a range of cargos. The drug delivery system is based upon the synthesis of self-assembled spherical polymer vesicles known as polymersomes. Polymersomes are biocompatible and stable making them ideal for the development of drug delivery systems.
Paul Clarke, Managing Director of Postnova Analytics (UK) said: "Researchers at UCL purchased the Postnova AF2000 system to work on the purification and characterisation of polymersomes being synthesised for the treatment of several diseases including cancer, infections and neurological disorders. The project is part of a multidisciplinary effort aimed toward the design of personalised nanomedicines. We are delighted to provide UCL with an analytical tool that will assist them in their ground breaking work".
Guiseppe Battaglia, Professor of Molecular Bionics, within the Chemistry Department at UCL commented: “Having identified Field Flow Fractionation as the best technique to purify and characterise polymersomes we elected to purchase an AF2000 system from Postnova as it allows us to quantify the materials both in terms of size as well as shape. Such an effort is critical to both elucidate important structure/function relation, as well as to expedite the necessary quality control associated with clinical translation.
The Postnova AF2000 is a high performance Field Flow Fractionation (FFF) platform for separation of proteins, macromolecules and nanoparticles. Modular in design, the AF2000 incorporates the combined experience, expertise and technological advances from Postnova Analytics' nearly two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 offers more flexibility, better performance and more robust results than any system before.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance